



HRIDROGA (HEART FAILURE): SYSTEMATIC INTEGRATIVE REVIEW OF AYURVEDIC AND CONTEMPORARY CARDIOLOGICAL APPROACHES

Amaan Siddiqui*, Abhishek Bhushan Sharma*, Charu Sharma*, Umesh Kumar*

1. Postgraduate Scholar,
Department of Kayachikitsa,
Quadra Institute of Ayurveda, Roorkee, Uttarakhand, India.

2. Professor MD (Ayurveda),
Department of Kayachikitsa,
Quadra Institute of Ayurveda, Roorkee, Uttarakhand, India.

3. Professor MD (Ayurveda),
Department of Kayachikitsa,
Quadra Institute of Ayurveda, Roorkee, Uttarakhand, India.

4. Consultant Internal Medicine (MBBS MD),
Rishyam Hospital, Roorkee, Uttarakhand, India

Abstract

Background: Heart failure continues to present significant challenges in global healthcare despite advances in modern therapeutics. The ancient Ayurvedic system offers a distinct perspective on cardiac disorders through the concept of Hridroga, which merits scientific exploration alongside contemporary cardiology.

Objective: This review examines the Ayurvedic understanding of Hridroga in relation to modern heart failure concepts, evaluating evidence for potential integrative management approaches.

Methods: We conducted a systematic literature search across PubMed, PMC, Google Scholar, and authenticated Ayurvedic classical repositories. Studies examining Hridroga, heart failure pathophysiology, Ayurvedic cardiovascular interventions, and integrative approaches were included from 1993 to 2025.

Results: Our analysis reveals meaningful parallels between Ayurvedic and contemporary understanding of cardiac dysfunction. Clinical and experimental evidence demonstrates

cardioprotective properties of several Ayurvedic interventions, particularly *Terminalia arjuna*, through mechanisms including antioxidant activity, anti-inflammatory effects, and neurohormonal modulation.

Conclusion: Evidence suggests that carefully selected Ayurvedic interventions may complement modern heart failure management when appropriately standardized and monitored. Further rigorous clinical investigation is warranted to establish optimal integrative protocols.

Keywords: Hridroga, Heart failure, Ayurveda, *Terminalia arjuna*, Integrative cardiology, Panchakarma

1. Introduction

Heart failure affects over 26 million individuals worldwide, representing a substantial public health concern.(1,2) Current mortality rates remain concerning, with approximately half of patients succumbing within five years of diagnosis despite contemporary therapeutic interventions.(3) Modern pharmacotherapy has expanded to include multiple drug classes—ACE inhibitors, beta-blockers, ARNIs, and SGLT2 inhibitors—yet clinical outcomes demonstrate room for improvement.(4)

The Ayurvedic medical tradition, documented over millennia, conceptualizes cardiac pathology through the framework of Hridroga (literally "heart disease").(5,6) While emerging from different philosophical foundations than biomedicine, Ayurvedic cardiovascular concepts exhibit intriguing correspondences with modern understanding, suggesting potential value in systematic investigation.(7,8)

1.1 Rationale for Integrative Review

Current heart failure management faces limitations including medication intolerance, treatment resistance, and incomplete symptom control.(9) Recent investigations have reported encouraging findings with specific Ayurvedic protocols, including improvements in ventricular function, symptom burden, and biomarker profiles.(10-12) These preliminary results justify comprehensive evaluation of integrative approaches.

1.2 Review Objectives

This systematic review aims to:

- Compare Ayurvedic Hridroga concepts with contemporary heart failure classification
- Analyze pathophysiological understanding in both medical systems
- Evaluate experimental and clinical evidence for Ayurvedic cardiovascular interventions
- Propose frameworks for safe integrative practice
- Identify priorities for future investigation

2. Methodology

2.1 Search Strategy

Our comprehensive search utilized multiple databases: PubMed, PubMed Central, Google Scholar, ScienceDirect, and Cochrane Library, spanning publications from 1993 through January 2025. Search terminology included: "Hridroga," "heart failure Ayurveda," "*Terminalia arjuna*," "Ayurvedic cardiology," "Panchakarma cardiovascular," and "integrative heart failure management."

2.2 Classical Ayurvedic Sources

We reviewed primary Ayurvedic texts including:

- Charaka Samhita (specifically Sutra Sthana and Chikitsa Sthana sections)
- Sushruta Samhita (Uttara Tantra)
- Madhava Nidana
- Bhela Samhita

Digital versions were accessed through the National Institute of Indian Medical Heritage library.

2.3 Selection Criteria

Inclusion criteria:

- Studies addressing Hridroga or heart failure from either medical perspective
- Clinical trials, observational studies, and experimental investigations
- Phytochemical, pharmacological, or clinical research on Ayurvedic cardiovascular herbs
- Peer-reviewed publications in indexed journals

Exclusion criteria:

- Insufficient methodological detail
- Publications lacking peer review (excluding classical texts)
- Redundant or duplicate reports
- Studies with substantial missing data

3. Ayurvedic Conceptualization of Hridaya and Hridroga

3.1 Hridaya: Physiological Understanding

In Ayurvedic physiology, the heart (Hridaya) represents one of three vital organs (Trimarma) and is counted among ten sites essential for life.(13,14) The etymology itself suggests functional understanding—"Hri" relates to collecting or attracting blood, while "Daya" implies giving or distributing, essentially describing circulatory mechanics.(15)

Classical texts contain surprisingly sophisticated circulatory concepts:

- Continuous circulation of Rasa (plasma-like nutrient fluid) in cyclical fashion
- Variable velocity of flow through different tissue beds
- Distribution from heart throughout the body via channels (Siras)(16,17)

3.2 Structural Conceptualization

Ancient texts describe cardiac tissue composition in terms of Dhatus (tissue elements):

- The outer protective layer corresponds to Meda Dhatu (adipose tissue)
- The muscular wall relates to Mamsa Dhatu (muscle tissue)
- The inner lining connects with Rasa and Rakta Dhatus (plasma and blood constituents)(18)

While terminology differs from modern anatomy, these descriptions demonstrate systematic observation of cardiac structure.

3.3 Classification of Hridroga

Ayurvedic nosology categorizes Hridroga into five types based on predominant dosha involvement:(19,20)

Vataja Hridroga: Characterized by stabbing pain, restlessness, and irregular rhythm—showing clinical overlap with ischemic disease and arrhythmias

Pittaja Hridroga: Features burning sensations and inflammatory processes—corresponding to inflammatory cardiac conditions

Kaphaja Hridroga: Presents with heaviness, fluid retention, and diminished cardiac performance—paralleling congestive heart failure presentations

Tridoshaja Hridroga: Manifests combined features from all three doshas

Krimija Hridroga: Attributed to microbial factors—conceptually related to infectious endocarditis and rheumatic heart disease

3.4 Pathogenetic Mechanisms

Ayurvedic disease development (Samprapti) in cardiac disorders involves several key concepts:(21,22)

Agnimandya: Impaired metabolic fire leading to incomplete tissue transformation

Ama formation: Accumulation of incompletely processed metabolic products

Srotorodha: Obstruction of micro-channels at tissue level

Dhamani Pratichaya: Accumulation within vessel walls, conceptually similar to atherosclerotic changes

Vyana Vayu disturbance: Dysfunction of the dosha governing circulation and cardiac contractility

Margavarana: Pathway obstruction from Kapha-Medas accumulation

The concept of Margavarana Hridroga particularly deserves attention, as it describes vessel coating (Upalepa) by Kapha and Medas, leading to blood stagnation and progressive vascular compromise.(23)

4. Contemporary Understanding of Heart Failure

4.1 Current Definitions and Classification

Modern cardiology defines heart failure as a clinical syndrome resulting from impaired ventricular function, whether from filling or ejection abnormalities.(24) Current classification schemes include:

Ejection Fraction-Based Categories:

- HFrEF (reduced EF): LVEF \leq 40%
- HFmrEF (mildly reduced): LVEF 41-49%
- HFpEF (preserved EF): LVEF \geq 50%(25)

Progression Staging (ACC/AHA):

- Stage A: Risk factors present without structural changes
- Stage B: Structural abnormalities without symptoms
- Stage C: Structural disease with symptomatic manifestations
- Stage D: Advanced disease requiring specialized interventions(26)

4.2 Pathophysiological Understanding

Contemporary understanding recognizes heart failure as a progressive syndrome involving multiple interconnected mechanisms:(27-29)

Neurohormonal dysregulation:

- Activation of renin-angiotensin-aldosterone axis
- Sympathetic nervous system upregulation
- Altered natriuretic peptide dynamics

Cellular and molecular alterations:

- Myocyte hypertrophy and programmed cell death
- Progressive fibrosis
- Disrupted calcium handling
- Mitochondrial dysfunction
- Inflammatory cascade activation
- Oxidative stress accumulation

Hemodynamic consequences:

- Altered loading conditions
- Ventricular geometric remodeling
- Diminished cardiac output
- Compensatory mechanisms ultimately becoming maladaptive

Systemic effects:

- Congestion in pulmonary and systemic circulations
- Reduced perfusion to vital organs
- Progressive renal dysfunction
- Muscle wasting and cachexia
- Sustained inflammatory state with elevated cytokines

4.3 Current Therapeutic Approaches

Guideline-directed therapy for heart failure encompasses:(30,31)

Pharmacological management:

- Renin-angiotensin system inhibitors
- Beta-adrenergic blockers
- Mineralocorticoid antagonists
- Nephrylsin inhibitors combined with ARBs
- SGLT2 inhibitors showing benefit across ejection fraction spectrum
- Diuretics for congestion management
- Digoxin for rate control in specific cases
- Ivabradine for heart rate reduction
- Newer agents including GLP-1 agonists under investigation

Device-based interventions:

- Implantable defibrillators for sudden death prevention
- Cardiac resynchronization for electrical dyssynchrony
- Mechanical circulatory support

Surgical options:

- Revascularization procedures
- Valvular interventions
- Cardiac transplantation

Despite these advances, readmission rates remain problematic, with nearly one-quarter of patients requiring hospitalization within 30 days of discharge.(32) This underscores the need for comprehensive management strategies.

5. Comparative Analysis: Bridging Two Medical Systems**5.1 Conceptual Convergences**

Despite different terminological frameworks, substantive parallels emerge:

Metabolic dysfunction: Ayurvedic Agnimandya correlates with modern understanding of metabolic derangement and mitochondrial impairment

Toxic accumulation: Ama formation conceptually aligns with oxidative stress products and inflammatory mediators

Vascular obstruction: Srotorodha and Margavarana parallel atherosclerotic processes and coronary obstruction

Circulatory regulation: Vyana Vayu dysfunction corresponds to autonomic imbalance and impaired cardiac performance

Lipid abnormalities: Kapha-Medasa accumulation relates to dyslipidemia and endothelial dysfunction

Inflammatory states: Rakta-Pitta vitiation reflects inflammatory cardiovascular conditions

Tissue depletion: Dhatu Kshaya parallels cardiac cachexia and muscle wasting

5.2 Shared Mechanistic Recognition

Both systems acknowledge:

- Central importance of circulatory function
- Role of inflammatory processes in disease progression
- Contribution of metabolic disturbances
- Impact of neurohormonal imbalance
- Progressive nature requiring early intervention
- Systemic manifestations beyond primary organ involvement

This convergence suggests potential for meaningful integration when approached systematically and scientifically.

6. Ayurvedic Pharmacological Interventions: Evidence Review

6.1 Terminalia arjuna: Most Extensively Studied Cardiovascular Herb

Terminalia arjuna (Roxb.) Wight & Arn., commonly known as Arjuna, has received substantial research attention as the primary Ayurvedic cardiac medication.(33)

Traditional applications: Bark preparations, particularly decoctions with milk (Arjuna Ksheera Paka), have been used traditionally for cardiac pain and dysfunction. The herb appears in classical texts as part of the Hridya Mahakashaya, a group of cardiac remedies.(34)

Chemical constituents: Phytochemical analysis has identified:(35,36)

- Triterpene compounds: arjunolic acid, arjunic acid, terminic acid
- Flavonoid compounds: quercetin, kaempferol, luteolin
- Tannins including ellagic and gallic acids
- Oligomeric proanthocyanidins
- Various minerals: calcium, magnesium, zinc, copper
- Glycosidic saponins

Documented pharmacological effects:

Experimental studies have demonstrated:(37-40)

Cardiac contractility enhancement: Research indicates positive inotropic activity, improving left ventricular performance through mechanisms attributed to saponin constituents.

Antioxidant properties: Studies show enhanced activity of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), reduced lipid peroxidation, and protection against ischemia-reperfusion injury. The extract induces cardiac heat shock protein 72, suggesting stress response activation.

Anti-inflammatory activity: Investigations demonstrate reduced levels of tumor necrosis factor-alpha and interleukin-6, with modulation of inflammatory signaling pathways.

Lipid metabolism effects: Clinical trials have shown reductions in total cholesterol, LDL cholesterol, and triglycerides, with increases in HDL cholesterol. Mechanistic studies suggest HMG-CoA reductase inhibition.

Vascular effects: Research indicates coronary vasodilatory properties and mild blood pressure reduction.

Protection against cardiotoxicity: Experimental models demonstrate protection against isoproterenol-induced injury, doxorubicin cardiotoxicity, and catecholamine-mediated damage.

Clinical evidence summary:

Bharani et al. (1995) conducted a placebo-controlled trial in severe heart failure (NYHA Class IV). Patients receiving 500 mg Arjuna extract three times daily for two weeks showed improved ejection fraction, reduced end-systolic volume, and enhanced contractility parameters.(41)

Angina studies have reported reduced anginal frequency, improved exercise tolerance, and enhanced quality of life, with some parameters showing comparability to isosorbide mononitrate.(42,43)

Dwivedi et al. (2016) performed a larger randomized controlled trial with standardized extract (750 mg twice daily) in 100 chronic heart failure patients. While primary endpoint (LVEF change at 12 weeks)

was not significant, the study demonstrated preserved antioxidant capacity, improved functional measures in subgroups, and enhanced quality of life with excellent tolerability.(44)

Experimental heart failure models by Parveen et al. demonstrated restored baroreflex sensitivity, improved cardiac function, reduced hypertrophy, and attenuated oxidative and inflammatory markers.(45)

Mechanistic investigations by Kumar et al. showed significant attenuation of cardiac dysfunction with reduced injury biomarkers, maintained antioxidant systems, and decreased inflammatory mediators.(46)

6.2 Other Ayurvedic Cardiovascular Herbs

Pushkarmoola (*Inula racemosa*): Traditional use for angina with reported coronary vasodilatory and anti-arrhythmic properties. Often used in combination formulations like Pushkara-Guggulu.(47)

Guggulu (*Commiphora mukul*): Investigated primarily for lipid-lowering effects with additional anti-atherosclerotic and anti-inflammatory properties.

Ashwagandha (*Withania somnifera*): Adaptogenic herb showing cardioprotective effects against stress-induced damage and cortisol-mediated injury.

Lasuna (*Allium sativum* - Garlic): Well-studied for antiplatelet effects, blood pressure reduction, cholesterol lowering, and antioxidant properties.

Amalaki (*Emblica officinalis*): Rich in ascorbic acid and polyphenols with documented cardioprotective and antioxidant effects.

Jatamansi (*Nardostachys jatamansi*): Traditional cardiac sedative with anxiolytic properties and potential anti-arrhythmic effects.

6.3 Classical Formulations

Traditional multi-herb preparations include:(48,49)

- Arjuna Ksheera Paka (Arjuna with milk decoction)
- Hridayarnava Rasa (complex formulation for cardiac strength)
- Hridroga Chintamani Rasa (multi-ingredient cardiac tonic)
- Prabhakara Vati (for angina and palpitations)
- Dashmoola (ten-root formulation for Vata-related disorders)

7. Panchakarma: Bio-purification Procedures

7.1 Purification Therapies (Shodhana)

Panchakarma represents systematic detoxification aimed at removing accumulated toxins and rebalancing physiological functions:(50,51)

Vamana (therapeutic emesis): Indicated for Kaphaja predominant conditions, removes excess Kapha from upper body regions and may benefit respiratory congestion in heart failure.

Virechana (therapeutic purgation): Eliminates Pitta and metabolic toxins, potentially improving lipid metabolism. Case reports suggest benefits in atherosclerotic burden reduction.(52)

Basti (medicated enema): Particularly Lekhana Basti (fat-reducing) and Anulomana Basti (Vata-regulating) variants may improve autonomic balance and enhance medication bioavailability.

Nasya (nasal medication): Addresses conditions affecting higher centers, assists with stress management, and potentially improves cerebral circulation.

Raktamokshana (bloodletting): Limited application in specific Rakta-Pitta conditions, generally not indicated in heart failure.

7.2 Palliative Therapies (Shamana)

Hridaya Dhara: Continuous streaming of medicated oils or decoctions over the cardiac region, reported to reduce anxiety, improve cardiac function, and balance autonomic tone.(53)

Abhyanga (therapeutic massage): Oil massage improving circulation, reducing Vata aggravation, and promoting stress reduction.

Swedana (controlled fomentation): Improves peripheral circulation and may reduce edema when carefully applied, though contraindicated in acute decompensation.

7.3 Clinical Evidence for Panchakarma

Recent investigations report:(54,55)

- Angiographic changes suggesting reduced coronary blockages with comprehensive protocols
- Improved myocardial strain patterns on advanced echocardiography
- Favorable biomarker changes including inflammatory markers and lipid profiles
- Significant quality of life improvements across multiple assessment domains

However, these studies require replication with larger samples and rigorous controls.

8. Dietary and Lifestyle Recommendations

8.1 Beneficial and Harmful Dietary Patterns

Recommended foods (Pathya):(56) Foods should be light and easily digestible, warm, and freshly prepared. Specific recommendations include green gram, aged rice, garlic and ginger in moderation, pomegranate, grapes, buttermilk, low-fat dairy, and adequate warm water intake.

Foods to avoid (Apathya): Heavy, oily, and fried preparations should be minimized. Excessive salt intake should be avoided. Specific restrictions include curd at night, fermented foods, red meat, processed foods, excessive cold water or ice, irregular sleep patterns, and suppression of natural urges.

8.2 Lifestyle Guidelines

Daily routine (Dinacharya): Recommendations include early rising, regular meal timing, moderate exercise suited to individual constitution, stress management through meditation and breathing practices, and adequate sleep duration.

Seasonal adjustments (Ritucharya): Dietary and lifestyle modifications based on seasonal variations, with Panchakarma procedures often recommended during seasonal transitions.

8.3 Yoga and Breathing Practices

Specific practices for cardiac health include:(57,58)

- Pranayama techniques: alternate nostril breathing, bee breath
- Gentle postures: relaxation pose, supported forward bends, modified inversions
- Meditation and mindfulness practices
- Modified sun salutations in stable conditions

Research has documented:

- Improved heart rate variability
- Blood pressure reduction
- Enhanced parasympathetic activity
- Better stress coping
- Quality of life improvements

9. Clinical Case Evidence

9.1 Congestive Heart Failure Case

A 68-year-old male with chronic heart failure (LVEF 25%) presented with dyspnea on exertion, orthopnea, bilateral edema, abdominal distension, and poor appetite.(59)

Ayurvedic diagnosis: Kaphaja-Vataja Hridroga with fluid accumulation

Treatment approach: Arjuna bark powder 3g twice daily, Punarnava Mandur 500mg twice daily, Dashmoola decoction 40ml twice daily, dietary sodium restriction, and gentle external therapies. Conventional medications continued.

Outcomes: After two months, ejection fraction improved to 40%, ECG normalized, symptoms resolved, and improvements maintained at two-year follow-up with enhanced functional capacity.

9.2 Valvular Disease Case

A patient scheduled for mitral valve surgery for rheumatic stenosis (valve area 1.3 sq cm) underwent comprehensive Ayurvedic treatment including herbal protocols, Panchakarma procedures, and dietary modifications for 11 months.(60)

Results: Advanced cardiovascular imaging demonstrated valve area increase to 3.52 sq cm with significant symptom improvement, leading to postponement of planned surgery. This suggests potential benefits even in structural heart disease, though requiring verification in controlled trials.

9.3 Low Ejection Fraction Case

A 26-year-old female with LVEF <40% received polyherbal formulation, Panchakarma (including Virechana and Basti), dietary modifications emphasizing potassium-rich foods, and sodium restriction.(61)

Outcomes: Improved ejection fraction, enhanced functional capacity, reduced NT-proBNP levels, and better quality of life scores were documented.

While these cases show promise, they represent preliminary evidence requiring validation through rigorous controlled studies.

10. Proposed Integration Framework

10.1 Stage-Based Integration Approach

Stage A (at-risk patients): *Modern approach:* Risk factor modification, lifestyle interventions *Ayurvedic additions:* Rejuvenative therapies (Rasayana), daily and seasonal regimens, preventive detoxification *Integration:* Combined dietary counseling, stress management techniques, preventive herbal supplementation where appropriate

Stage B (structural disease without symptoms): *Modern approach:* ACE inhibitors/ARBs, beta-blockers, statins *Ayurvedic additions:* Cardiac herbs (Arjuna, Pushkarmoola), periodic purification *Integration:* Herbal adjuncts with careful monitoring, comprehensive lifestyle optimization

Stage C (symptomatic heart failure): *Modern approach:* Full guideline-directed therapy, device consideration *Ayurvedic additions:* Specific herbal protocols, tailored Panchakarma, symptom-targeted therapies *Integration:* Supervised combination approach with regular monitoring and biomarker tracking

Stage D (advanced/refractory): *Modern approach:* Advanced therapies, mechanical support, transplant evaluation *Ayurvedic additions:* Palliative Rasayana, quality of life support, psycho-spiritual care *Integration:* Complementary supportive measures focusing on comfort and wellbeing

10.2 Ayurvedic Polypill Concept

Drawing from the modern polypill strategy, an Ayurvedic cardiovascular combination could address multiple risk factors:(62)

Potential components:

- Arjuna for inotropic support and antioxidant effects
- Guggulu for lipid reduction
- Pushkarmoola for anti-anginal effects
- Lasuna for antiplatelet and antihypertensive properties
- Amalaki for antioxidant capacity
- Jatamansi for anxiolytic and anti-arrhythmic potential

Targeted mechanisms: Dyslipidemia, hypertension, oxidative stress, inflammation, platelet activation, and psycho-emotional factors

10.3 Monitoring Recommendations

Conventional parameters: Ejection fraction, cardiac output measurements, natriuretic peptides, electrocardiography, exercise tolerance testing, validated quality of life instruments

Ayurvedic assessments: Dosha evaluation through pulse and other traditional diagnostics, digestive capacity assessment, constitutional analysis, symptom-specific parameters

Integrated approach: Combined biomarker panels, comprehensive functional assessments, patient-reported outcomes, systematic safety monitoring including potential interactions

11. Safety and Interaction Considerations

11.1 Safety Profiles

Most Ayurvedic cardiovascular herbs demonstrate reasonable safety when properly used:(63,64)

Terminalia arjuna: Generally well-tolerated with extensive traditional use. Clinical trials report minimal adverse effects, primarily mild gastrointestinal disturbances in some individuals.

Potential concerns: Product quality varies substantially. Heavy metal contamination, inadequate standardization, and limited long-term safety data for some formulations remain concerns. Theoretical interactions with anticoagulants require attention.

11.2 Herb-Drug Interactions

Important considerations:

Arjuna with beta-blockers: Potential additive effects requiring heart rate and blood pressure monitoring

Guggulu with statins: Possible additive lipid-lowering effects necessitating liver function monitoring

Garlic with anticoagulants: Increased bleeding risk requiring close observation

Diuretic herbs with loop diuretics: Electrolyte and renal function monitoring essential

11.3 Quality Assurance

Essential requirements: Good Manufacturing Practice certification, constituent standardization, heavy metal testing, microbial screening, botanical authentication, and batch consistency verification are all critical for safe integration.

12. Knowledge Gaps and Research Priorities

12.1 Current Evidence Limitations

Clinical evidence gaps: Large multicenter randomized trials are lacking. Long-term outcome studies are needed. Optimal dosing and treatment duration remain undefined for many interventions. Direct comparisons with standard therapies are absent. Detailed mechanistic studies at molecular levels require expansion.

Standardization challenges: Herbal preparation variability, lack of universal quality markers, need for pharmacopoeial standards, and bioequivalence studies all represent important gaps.

Safety data needs: Comprehensive pharmacovigilance systems, complete long-term safety profiles, thorough interaction databases, and pregnancy/lactation safety information are insufficient.

12.2 Future Directions

Clinical investigation priorities:

- Phase III trials of standardized Arjuna in heart failure populations
- Comparative effectiveness research between Ayurvedic and conventional approaches
- Combination therapy trials examining modern therapy plus Ayurvedic protocols
- Economic analyses evaluating cost-effectiveness

- Patient-centered outcome research

Mechanistic research needs:

- Proteomic and metabolomic profiling of Ayurvedic interventions
- Gene expression studies
- Gut microbiome modulation research
- Epigenetic effect investigations
- Detailed neurohormonal mechanism elucidation

Technology integration opportunities:

- Artificial intelligence for constitutional assessment and protocol personalization
- Wearable device integration for continuous monitoring
- Telemedicine platforms for integrative care delivery
- Digital therapeutic development
- Predictive modeling for treatment response

Translational research areas:

- Novel drug discovery from Ayurvedic sources
- Advanced delivery systems for phytochemicals
- Ayurvedic diagnostic biomarker development
- Standardized Panchakarma protocol creation
- Healthcare system integration frameworks

12.3 Implementation Considerations

Healthcare system needs: Integrative cardiology center development, dual-competency training programs, insurance coverage for evidence-based interventions, regulatory harmonization, and patient education initiatives all require attention.

13. Discussion

13.1 Theoretical Integration

This systematic review reveals substantial common ground between Ayurvedic Hridroga concepts and contemporary heart failure understanding. Despite emerging from different epistemological traditions, both recognize cardiac disorders as multifactorial conditions involving circulatory dysfunction, metabolic disturbances, inflammatory processes, and regulatory system imbalances.

The Ayurvedic concept of impaired metabolic fire (Agnimandya) producing toxic metabolites (Ama) parallels modern understanding of metabolic dysfunction and oxidative stress accumulation. Channel obstruction (Srotorodha) and vascular coating (Margavarana) conceptually align with atherosclerotic processes. Circulatory regulatory dysfunction (Vyana Vayu vitiation) corresponds to autonomic imbalance and impaired cardiac performance.

13.2 Clinical Evidence Interpretation

Terminalia arjuna represents the most investigated Ayurvedic cardiac intervention. Early smaller studies suggested dramatic improvements in cardiac function, while more recent larger controlled trials show more modest but potentially meaningful benefits in functional capacity, quality of life, and biomarker preservation. This pattern is not unusual in phytomedicine research and likely reflects factors including study design evolution, patient population differences, preparation standardization, and treatment duration variations.

Panchakarma procedures show preliminary evidence for cardiovascular benefits including potential improvements in vascular morphology, inflammatory markers, and functional parameters. However, current evidence comes primarily from case series and small studies lacking rigorous controls, limiting definitive conclusions.

Polyherbal formulations combined with comprehensive Ayurvedic approaches show promise in case reports for improving cardiac function, including structural parameters. These require verification through controlled investigation.

13.3 Mechanistic Considerations

Ayurvedic cardiovascular interventions appear to operate through multiple complementary pathways:

- Reducing oxidative stress through antioxidant mechanisms
- Modulating inflammatory responses
- Influencing lipid metabolism
- Improving endothelial function
- Affecting neurohormonal balance
- Protecting mitochondrial function
- Inducing protective protein responses
- Restoring autonomic balance

These mechanisms complement rather than duplicate modern pharmacotherapy, suggesting potential for synergistic rather than merely additive effects.

13.4 Safety Considerations

Major Ayurvedic cardiovascular herbs demonstrate acceptable safety profiles in clinical investigations, with most adverse effects being mild and gastrointestinal in nature. However, product quality variability, standardization challenges, and potential drug interactions require systematic attention. The theoretical framework for integration must prioritize patient safety through quality assurance, interaction monitoring, and appropriate clinical oversight.

13.5 Study Limitations

This review has important limitations. Study heterogeneity in design and quality, limited availability of large rigorous trials, herbal preparation variability across investigations, potential publication bias, insufficient long-term outcome data, and limited comparative effectiveness evidence all affect interpretation strength.

14. Conclusion

Heart failure represents an escalating global challenge requiring comprehensive therapeutic strategies. This systematic review demonstrates meaningful convergence between ancient Ayurvedic cardiac disease conceptualization and modern heart failure understanding, despite different theoretical frameworks.

Current evidence supports cardioprotective potential for specific Ayurvedic interventions, particularly *Terminalia arjuna*, which shows consistent benefits through antioxidant, anti-inflammatory, and neurohormonal mechanisms. Panchakarma therapies and comprehensive Ayurvedic protocols demonstrate preliminary promise warranting further investigation.

Integrative approaches combining evidence-based modern pharmacotherapy with appropriately standardized Ayurvedic interventions offer potential advantages including multi-targeted mechanistic approaches addressing complex pathophysiology, enhanced patient-centered holistic care, potential

symptom and quality of life improvements, lifestyle modification support, and possible synergistic effects potentially reducing medication burden.

However, substantial knowledge gaps persist. Research priorities include large rigorous randomized trials, preparation and protocol standardization, detailed molecular mechanistic studies, long-term safety and efficacy data, economic analyses, and healthcare integration frameworks.

Moving from theoretical integration to evidence-based practice requires collaboration among Ayurvedic physicians, cardiologists, researchers, regulatory authorities, and healthcare systems. With appropriate scientific rigor, quality control, and safety monitoring, integrative cardiology may offer enhanced options for millions affected by heart failure globally.

The path forward demands careful, methodical investigation maintaining scientific standards while remaining open to potential contributions from traditional medical systems. Only through such rigorous yet open-minded inquiry can we determine whether and how Ayurvedic approaches might complement modern heart failure management.

Acknowledgments

We acknowledge classical Ayurvedic texts available through the National Institute of Indian Medical Heritage and extensive clinical research accessible through PubMed Central and other scientific repositories.

Conflict of Interest

None declared.

References

1. Shams P, Malik A, Chhabra L. Heart failure. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
2. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. *AME Med J*. 2020;5:15.
3. Tanai E, Frantz S. Pathophysiology of heart failure. *Compr Physiol*. 2015;6(1):187-214.
4. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail*. 2020;22(8):1342-56.
5. Rana D, Susmita S, Kar AC. Critical review on Hrudaya (Heart) and Hrudroga (Cardiovascular disorders) and its Nidana (Causative factors). *J Ayurveda Integr Med Sci*. 2022;7(5):91-5.
6. Murthy ARV, Singh RH. Ayurvedic concept of hridroga its present relevance. *Ancient Sci Life*. 1993;12:403-13.
7. Nishteswar K. Credential evidences of Ayurvedic cardio-vascular herbs. *Ayu*. 2014;35(2):111-2.
8. Mamgain P, Singh RH. A critical study of the concept of ischaemic heart disease in ayurveda. *Anc Sci Life*. 1993;12(3-4):331-8.
9. Gheorghide M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. *J Am Coll Cardiol*. 2013;61(4):391-403.
10. Mithra MP. Ayurvedic approach to treat Hridroga (valvular heart disease): A case report. *J Ayurveda Integr Med*. 2019;10(1):69-72.
11. Dwivedi S, Chopra D. Revisiting Terminalia arjuna - An ancient cardiovascular drug. *J Tradit Complement Med*. 2014;4(4):224-31.

12. Sonare C, Wackchaure M. Treatment of heart failure with low ejection fraction with polyherbs and panchakarma: A case report. *J Prev Med Holist Health*. 2023;9(1):24-8.
13. Charaka Samhita, Sutra Sthana, Kiyantashiraseeyam Adhyayam, 17/06. Available from: <https://niimh.nic.in/ebooks/ecaraka>
14. Sushruta Samhitha, Uttara Tantra, Hrudyaroga pratishedham, 43/05. Available from: <http://niimh.nic.in/ebooks/esushruta>
15. Hebbar JV. Hrid Roga: Causes, types, symptoms of heart disease as per Ayurveda. *Easy Ayurveda*. 2023 Aug 3. Available from: <https://www.easyayurveda.com/2017/08/08/hridroga-chikitsa/>
16. Athavale VB. *Cardiology in ayurveda*. 1st ed. Chaukhamba Sanskrit Pratishtan; 1999.
17. Sastry JLN, Nisteswar K. *Ayurvedic management for heart diseases*. 1st ed. Chaukhamba Sanskrit Pratishtan; 2014.
18. Panda AK, Mohapatra JK, Rana D. Ayurvedic review on diagnosis and management of Hridroga with the special reference to cardiovascular disease. *J Ayurveda Integr Med Sci*. 2020;5(3):231-8.
19. Madhav Nidana, Madhukosha teeka, Hrudroga nidanam 29/01. Available from: <https://niimh.nic.in/ebooks/madhavnidana>
20. Charaka Samhita, Chikitsa Sthana, Trimarmiya Chikitsa, 26/75-85.
21. Nair R. Congestive heart failure- Ayurvedic treatment, diet, exercises, research papers, yoga & pranayama. *Ayurveda PC*. 2022 Apr 28. Available from: <https://ayurvedapc.blog/2022/04/28/congestive-heart-failure/>
22. Mangain P, Singh RH. Etiopathological and diagnostic study of Margavaranajanya Hridroga w.s.r. to coronary artery disease - An observational study. *Ayu*. 2018;39(2):88-94.
23. Panda AK, Rana D, Lepcha O. Margavaranajanya Hridroga: Understanding coronary artery disease through Ayurvedic lens. *J Ayurveda Integr Med*. 2024;15(2):123-9.
24. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2016;37(27):2129-200.
25. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. *J Am Coll Cardiol*. 2022;79(17):e263-e421.
26. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. *Circulation*. 2013;128(16):e240-327.
27. Braunwald E. The pathogenesis of congestive heart failure: then and now. *Medicine*. 1991;70(1):68-79.
28. Francis GS. Pathophysiology of chronic heart failure. *Am J Med*. 2001;110(7A):37S-46S.
29. Kemp CD, Conte JV. The pathophysiology of heart failure. *Cardiovasc Pathol*. 2012;21(5):365-71.
30. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599-726.
31. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nat Rev Cardiol*. 2016;13(6):368-78.
32. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA*. 2013;309(4):355-63.
33. Maulik SK, Talwar KK. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. *Curr Sci*. 2012;102(10):1381-91.
34. Charaka Samhita, Sutra Sthana, Shadvirechanashatashritiya Adhyaya, 4/13.
35. Amalraj A, Gopi S. Biological activities and medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn. *J Tradit Complement Med*. 2017;7(1):65-78.
36. Kapoor D, Vijayvergiya R, Dhawan V. Terminalia arjuna in coronary artery disease: Ethnopharmacology, pre-clinical, clinical & safety evaluation. *J Ethnopharmacol*. 2014;155(2):1029-45.
37. Dwivedi S, Agarwal MP. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary heart disease. *J Assoc Physicians India*. 1994;42(4):287-9.
38. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. *Int J Cardiol*. 1995;49(3):191-9.

39. Parveen A, Babbar R, Agarwal S, Kotwani A, Fahim M. Terminalia arjuna enhances baroreflex sensitivity and myocardial function in isoproterenol-induced chronic heart failure rats. *J Cardiovasc Pharmacol Ther.* 2012;17(2):199-207.
40. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). *J Pharm Pharmacol.* 2009;61(11):1529-36.
41. Bharani A, Ganguly A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind placebo-controlled crossover study comparing Terminalia arjuna with isosorbide mononitrate. *Indian Heart J.* 2002;54(2):170-5.
42. Dwivedi S, Jauhari R, Varshney A, Sreenivas V. Terminalia arjuna Wight & Arn. protects the myocardium against ischaemic-reperfusion injury: role of oxygen free radicals. *J Ethnopharmacol.* 2006;106(2):238-45.
43. Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. *Indian Heart J.* 2002;54(2):170-5.
44. Dwivedi S, Chopra D, Gupta AK, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial. *Phytomedicine.* 2016;23(11):1211-9.
45. Parveen A, Babbar R, Agarwal S, Kotwani A, Fahim M. Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. *Cardiovasc Toxicol.* 2011;11(1):48-57.
46. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. Cardioprotective effect of Terminalia arjuna against oxidative stress induced by catecholamines. *J Pharm Pharmacol.* 2011;63(1):136-42.
47. Singh R, Singh RP, Batiwala PG, Upadhyay BN, Tripathi SN. Puskara-Guggulu an antianginal and hypolipemic agent in coronary heart disease (CHD). *J Res Ayurveda Siddha.* 1991;12:1-18.
48. Laddha AP, Chawda MB, Kulkarni YA. Cardioprotective effect of Hrudroga Chintamani Rasa in isoproterenol induced cardiotoxicity in male Sprague Dawley rats. *J Diabetes Metab Disord.* 2022;21(2):1261-70.
49. The Ayurvedic Pharmacopoeia of India. Part I, Volume I-IX. 1st ed. New Delhi: Ministry of Health and Family Welfare, Department of AYUSH, Government of India; 2001-2016.
50. Panda AK, Kar S. Panchakarma-based detoxification procedures can regulate the hepato-renal dysfunction: A case study. *Int J AYUSH Case Rep.* 2023;7(2):103-10.
51. Kaware R, Khan S. Role of Ayurveda-based diet and Panchakarma therapy on quantitative change in coronary atherosclerosis in known CAD assessed by quantitative CT coronary angiography. *Asian J Cardiol Res.* 2023;6(1):125-31.
52. Rohit S, Hanchate M. Effect of the Sampurna Hriday Shuddhikaran (SHS) model in heart failure patients in India: A prospective study. *J Adv Med Med Res.* 2024;13(16):46-60.
53. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med.* 2005;2(4):465-73.
54. Rohit S, Pramod M, Rahul M, Gurudatta A, Pravin G, Dinesh P. Impact of Ayurveda-based ischemia reversal program on reduction of resting myocardial ischemia studied with speckle-tracking global longitudinal strain imaging. *J Indian College Cardiol.* 2022;12(3):106-10.
55. Kar S, Panda AK. Ayurvedic approaches for the prevention and treatment of coronary artery disease: Moving from theory to clinical practice. *J Prev Med Holist Health.* 2025;11(1):16-22.
56. Sushruta Samhita, Sutra Sthana, Annapanavidhi Adhyaya, 46/467-468.
57. Sharma H, Swetanshu, Singh P. Role of yoga in cardiovascular diseases. *Curr Probl Cardiol.* 2024;49(1):102032.
58. Manchanda SC, Madan K. Yoga and meditation in cardiovascular disease. *Clin Res Cardiol.* 2014;103(9):675-80.
59. Singh M, Garg S, Garg GP. Integrative management of congestive cardiac failure (Hrudrog) with Ayurveda and modern medicine: A case report. *J Ayurveda Integr Med Sci.* 2021;6(2):179-84.

60. Mithra MP. Ayurvedic approach to treat Hridroga (valvular heart disease): A case report. *J Ayurveda Integr Med.* 2019;10(1):69-72.
61. Sonare C, Wackchaure M. Treatment of heart failure with low ejection fraction with polyherbs and panchakarma: A case report. *J Prev Med Holist Health.* 2023;9(1):24-8.
62. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. *BMJ.* 2003;326(7404):1419-23.
63. Shaito A, Thuan DTB, Phu HT, et al. Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. *Front Pharmacol.* 2020;11:422.
64. Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolemic effects of Terminalia arjuna tree-bark powder: A randomized placebo-controlled trial. *J Assoc Physicians India.* 2001;49:231-5.

